We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood-Based Liquid Biopsy Identifies Prostate Cancer Patients Likely to Develop Resistance to Docetaxel Treatment

By LabMedica International staff writers
Posted on 16 Nov 2021
A blood-based liquid biopsy method identified prostate cancer patients likely to become resistant to the commonly used chemotherapeutic agent docetaxel.

Docetaxel is a cytotoxic chemotherapeutic agent. More...
Because docetaxel is a cell-cycle-specific agent, it is cytotoxic to all dividing cells in the body. This includes tumor cells as well as hair follicles, bone marrow, and other germ cells. Docetaxel treatment has been shown to significantly improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC), and recently has been used as chemo-hormonal therapy in metastatic hormone-sensitive prostate cancer (mHSPC). However, a proportion of patients treated with DOC have inherent or acquired resistance.

Investigators at Queen Mary University of London (United Kingdom) examined the potential of a liquid biopsy approach for predicting which prostate cancer patients would become resistant to docetaxel.

For this study, the investigators employed the ANGLE (Guildford, United Kingdom) Parsortix blood filtration system to capture circulating tumor cells (CTCs) based on their larger size compared to other components in the blood, such as white blood cells.

Blood samples were obtained from 56 patients with advanced prostate cancer. The samples were taken before beginning docetaxel treatment, after the first dose of chemotherapy, before the fifth dose, and at the end of the treatment (after approximately six to eight months). The number of samples per patient ranged from two to four, and a total of 205 samples were analyzed.

Results revealed that patients were less likely to respond to docetaxel, their disease was more likely to recur or progress within three months, and they were more likely to die within 18 months if more than six CTCs per 7.5 milliliters of blood were detected before their first docetaxel dose. This compared to progression-free survival of 17 months and an overall survival time of three years for men with fewer than six CTCs detected per 7.5 milliliters of blood. In addition, it was found that the protein encoded by the KLK2 gene was significantly better at predicting time to disease progression and death than the current gold standard protein, prostate-specific antigen (PSA), which is encoded by the KLK3 gene.

“Our ability to collect and analyze CTCs before, during, and after treatment meant that we could monitor changes in CTCs in response to treatment,” said the author of the report, Caitlin Davies, a graduate research student at Queen Mary University of London. “We then looked for patterns in the data from men who responded or did not, or whose disease progressed sooner than others after treatment. Using these patterns, we can apply them to future patients with the goal to predict whether they will respond to therapy and preemptively decide on the best course of action that will have maximal benefit. For instance, an increase in CTC numbers may indicate a lack of response to treatment. Furthermore, by monitoring the appearance of potentially drug-resistant CTCs, we can change treatment tactics early on and in a patient-personalized and timely manner.”

Results of the study were presented in abstract delivered on November 10, 2021, at the British National Cancer Research Institute (NCRI) Festival.

Related Links:
Queen Mary University of London
ANGLE PLC



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.